{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":22,"n_cols":5,"rows_kept":22,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[12,2,12,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9911019564903321"]
[null,null,"Autore",null,"Sindhu Rakesh K"]
[null,null,"Titolo",null,"Bioactive-Based Nanotherapeutics"]
[null,null,"Pubbl/distr/stampa",null,"Newark : , : John Wiley & Sons, Incorporated, , 2025"]
[{"$nulls":4},"©2025"]
[null,null,"ISBN",null,"1-394-28734-8"]
[{"$nulls":4},"1-394-28733-X"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (771 pages)"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Cover -- Series Page -- Title Page -- Copyright Page -- Contents -- Preface -- Chapter 1 Basics of Nano-Bioactive Compounds and Their Therapeutic Potential -- 1.1 Introduction -- 1.2 Therapeutic Potential of Bioactive Compounds -- 1.2.1 Alkaloids -- 1.2.1.1 Medicinal Use of Alkaloids as Bioactive Molecule -- 1.2.2 Antibiotics -- 1.2.2.1 Medicinal Use of Antibiotics as Bioactive Molecule -- 1.2.3 Mycotoxins -- 1.2.3.1 Medicinal Use of Mycotoxins as Bioactive Molecule -- 1.2.4 Growth Factors -- 1.2.4.1 Medicinal Use of Growth Factors as Bioactive Compounds -- 1.2.5 Phenolics -- 1.2.5.1 Medicinal Use of Phenolics as Bioactive Compounds -- 1.3 Extraction Techniques for Obtaining Bioactive Compound -- 1.4 Novel Delivery Approach for Bioactive Compounds -- 1.5 Electrospinning -- 1.6 Micro- and Nanoencapsulation of Bioactive Compounds -- 1.7 Polymeric Nanoparticles (NPs) -- 1.8 Solid Lipid Nanoparticles -- 1.9 Nanoemulsions -- 1.10 Nanocrystals -- 1.11 Phytosomes -- 1.12 Therapeutic Potential of Nano-Bioactive Compounds -- 1.13 Conclusion -- References -- Chapter 2 Recent Techniques for Isolation of Bioactive Components from Plants -- 2.1 Introduction -- 2.2 Extraction Methods -- 2.2.1 Ultrasound-Assisted Extraction (UAE) -- 2.2.2 Supercritical Fluid Extraction (SFE) -- 2.2.3 Microwave-Assisted Extraction (MAE) -- 2.2.4 Molecular Imprinting Technology (MIT) -- 2.3 Recent Chromatographic Methods -- 2.3.1 Liquid Chromatography (LC) and Gas Chromatography (GC) -- 2.3.2 High-Performance Liquid Chromatography (HPLC) and Tandem Mass Spectrometry (MS/MS) -- 2.3.3 Supercritical Fluid Chromatography (SFC) -- 2.3.4 Two-"]
[{"$nulls":4},"Dimensional Chromatographic Approaches -- 2.4 Applications of Two-Dimensional Chromatographic Approaches -- 2.5 Hyphenated Techniques -- 2.6 Conclusion -- References -- Chapter 3 Bioactive-Based Nanocarriers for Inflammatory Diseases."]
[{"$nulls":4},"3.1 Inflammation and Diseases -- 3.2 Nanocarriers as Drug Delivery System -- 3.3 Nanocarriers and Inflammation -- 3.4 Inflammation in Central Nervous System -- 3.4.1 Etiology of CNS Inflammation -- 3.4.2 The Blood-Brain Barrier (BBB) -- 3.4.3 Immune Response -- 3.4.4 Clinical Manifestations -- 3.4.5 Diagnosis and Therapeutic Approaches -- 3.4.6 Chronic Inflammation -- 3.5 Ophthalmological Inflammation -- 3.5.1 Causes of Ophthalmological Inflammation -- 3.5.2 Symptoms of Ophthalmological Inflammation -- 3.5.3 Diagnosis and Treatment -- 3.6 Cardiovascular Inflammation -- 3.6.1 Significance of Inflammation -- 3.6.2 Factors Contributing to Inflammation -- 3.6.3 Role of Cytokines and Chemokines -- 3.6.4 Distinguishing Acute and Chronic Inflammation -- 3.6.5 Consequences of Chronic Inflammation -- 3.6.6 Treatment and Prevention -- 3.6.7 Use of Biomarkers -- 3.6.8 Ongoing Research -- 3.6.9 Nanocarriers Used in the Treatment of Cardiovascular Inflammation -- 3.7 Respiratory Inflammation -- 3.7.1 Origins of Respiratory Inflammation -- 3.7.2 Forms of Respiratory Inflammation -- 3.7.3 Disorders Associated with Respiratory Inflammation -- 3.7.4 Symptoms of Respiratory Inflammation -- 3.7.5 Treatment and Management -- 3.7.6 Prevention -- 3.7.7 Nanocarriers Used for the Treatment of Respiratory Inflammation -- 3.8 Inflammation in Gastric System -- 3.8.1 Causes of Gastric Inflammation -- 3.8.2 Types of Gastric Inflammation -- 3.8.3 Symptoms of Gastric Inflammation -- 3.8.4 Complications -- 3.8.5 Diagnosis -- 3.8.6 Treatment and Management -- 3.8.7 Prevention -- 3.8.8 Nanocarriers Used for the Treatment of Gastric Inflammation -- 3.9 Excretory System Inflammation -- 3.9.1 Causes of Excretory System Inflammation -- 3.9.2 Types of Urinary Tract Inflammation -- 3.9.3 Symptoms of Excretory System Inflammation -- 3.9.4 Complications -- 3.9.5 Diagnosis."]
[{"$nulls":4},"3.9.6 Treatment and Management -- 3.9.7 Prevention -- 3.9.8 Nanocarriers Used for Treatment of Excretory System Inflammation -- 3.10 Inflammation of the Reproductive System -- 3.10.1 Causes of Reproductive System Inflammation -- 3.10.2 Types of Reproductive System Inflammation -- 3.10.3 Symptoms of Reproductive System Inflammation -- 3.10.4 Complications -- 3.10.5 Diagnosis -- 3.10.6 Treatment and Management -- 3.10.7 Prevention -- 3.10.8 Nanocarriers Used for the Treatment of Reproductive Inflammation -- 3.11 Inflammation Associated with Dermatology -- 3.11.1 Causes of Dermatological Inflammation -- 3.11.2 Types of Dermatological Inflammation -- 3.11.3 Symptoms of Dermatological Inflammation -- 3.11.4 Complications -- 3.11.5 Diagnosis -- 3.11.6 Treatment and Management -- 3.11.7 Prevention -- 3.11.8 Nanocarriers Used for the Treatment of Inflammation Related to Dermatology -- 3.12 Muscular Inflammation -- 3.12.1 Causes of Muscular Inflammation -- 3.12.2 Types of Muscular Inflammation -- 3.12.3 Symptoms of Muscular Inflammation -- 3.12.4 Complications -- 3.12.5 Diagnosis -- 3.12.6 Treatment and Management -- 3.12.7 Prevention -- 3.12.8 Nanocarriers Used for the Treatment of Muscular Inflammation -- 3.13 Skeletal Inflammation -- 3.13.1 Causes of Skeletal Inflammation -- 3.13.2 Types of Skeletal Inflammation -- 3.13.3 Symptoms of Skeletal Inflammation -- 3.13.4 Complications -- 3.13.5 Diagnosis -- 3.13.6 Treatment and Management -- 3.13.7 Prevention -- 3.13.8 Nanocarriers Used for the Treatment of Skeletal Inflammation -- 3.14 Applications of Nanocarriers in Inflammation -- 3.15 Conclusion -- "]
[{"$nulls":4},"References -- Chapter 4 Bioactive-Based Nanocarriers for Dermal Diseases -- 4.1 Introduction -- 4.2 Skin Anatomy and Physiology: Implications for Drug Delivery -- 4.2.1 Structure of the Skin Layers -- 4.2.2 Epidermis: The Protective Barrier."]
[{"$nulls":4},"4.2.3 Dermis: Structural Support and Vascular Network -- 4.2.4 Hypodermis: Adipose Tissue and Insulation -- 4.2.5 Appendages: Hair Follicles, Sweat Glands, and More -- 4.3 Barrier Functions of the Skin -- 4.4 Transdermal Permeation Challenges -- 4.5 Factors Influencing Dermal Drug Penetration -- 4.5.1 Physicochemical Properties of the Drug -- 4.5.2 Formulation and Carrier Design -- 4.5.3 Skin Hydration and Moisture -- 4.5.4 Skin Integrity and Barrier Disorders -- 4.5.5 Anatomical Site and Skin Thickness -- 4.5.6 Circulation and Blood Flow -- 4.5.7 Skin pH and Microenvironment -- 4.6 Role of Nanocarriers in Enhancing Drug Penetration -- 4.6.1 Nanocarrier Types and Properties -- 4.6.2 Encapsulation and Solubilization -- 4.6.3 Enhanced Skin Penetration -- 4.6.4 Targeted Drug Delivery -- 4.6.5 Controlled Release -- 4.6.6 Safety and Biocompatibility -- 4.7 Types of Bioactive-Based Nanocarriers -- 4.8 Design Principles and Fabrication Techniques -- 4.8.1 Formulation Considerations -- 4.8.2 Techniques for Fabricating Bioactive-Based Nanocarriers -- 4.9 Characterization of Bioactive-Based Nanocarriers -- 4.9.1 Physicochemical Characterization -- 4.9.1.1 Dynamic Light Scattering -- 4.9.1.2 Zeta Potential Measurement -- 4.9.1.3 Fourier-Transform Infrared Spectroscopy -- 4.9.2 Morphological Analysis -- 4.9.2.1 Transmission Electron Microscopy -- 4.9.2.2 Scanning Electron Microscopy -- 4.9.3 Drug Release Profiling -- 4.9.3.1 In Vitro Release Studies -- 4.9.3.2 Franz Diffusion Cells -- 4.9.4 Stability Assessment -- 4.9.4.1 Accelerated Stability Studies -- 4.9.4.2 Thermal Analysis -- 4.10 Applications in Diverse Dermal Diseases -- 4.10.1 Acne: Targeted Delivery of Anti-Inflammatory Agents -- 4.10.1.1 Anti-Inflammatory Agents for Acne Treatment -- 4.10.1.2 Enhanced Drug Penetration -- 4.10.2 Psoriasis: Immune Modulation and Skin Barrier Restoration."]
[{"$nulls":4},"4.10.2.1 Immune Modulation Through Nanocarriers -- 4.10.2.2 Restoring Skin Barrier Function with Nanocarriers -- 4.10.2.3 Synergy in Action: Combined Approach for Comprehensive Psoriasis Management -- 4.10.3 Skin Cancers: Localized Chemotherapy and Photodynamic Therapy -- 4.10.4 Atopic Dermatitis: Addressing Inflammation and Pruritus -- 4.10.5 Bioactive-Based Nanocarriers for Chronic Wounds -- 4.11 Preclinical Studies: In Vivo and In Vitro -- 4.12 Challenges and Future Directions -- 4.13 Conclusion -- References -- Chapter 5 Nano-Based Nasal Delivery of Biomacromolecules: A Myriad of Opportunities -- 5.1 Biomacromolecules -- 5.2 Characteristics of Biomacromolecules and Delivery Challenges -- 5.2.1 Physicochemical Properties -- 5.2.2 Stability -- 5.2.3 Immunogenicity -- 5.2.4 Administration Route -- 5.3 Opportunities of Nasal Route -- 5.4 Main Factors in Nasal Cavity Affecting Delivery of Biomacromolecules -- 5.4.1 Nasal Epithelium and Absorption -- 5.4.2 Mucus Layer and Mucociliary Clearance -- 5.4.3 Enzymatic Activity -- 5.4.4 Other Factors -- 5.5 Nano-Based Delivery Systems as an Efficient Strategy to Improve Intranasal Administration of Biomacromolecules -- 5.5.1 Lipid-Based Delivery Systems -- 5.5.1.1 Liposomes -- 5.5.1.2 Lipid Nanoparticles: Solid Lipid Nanocarriers and Nanostructured Lipid Carriers -- 5.5.1.3 Nanoemulsions -- 5.5.2 Polymer-Based Delivery Systems -- 5.5.2.1 Polymeric Nanoparticles -- 5.5.2.2 Polymeric Micelles -- 5.5.2.3 Polymeric Nanocomplexes -- 5.5.2.4 Dendrimers -- 5.5.3 Inorganic Material-Based Delivery Systems -- 5.6 Proof of Concept: Biomacromolecules Administered by Intranasal Nano-Based Delivery Systems -- 5.6.1 Insulin -- 5.6.2 Glucagon-Like Peptide-1 and "]
[{"$nulls":4},"Its Analogs -- 5.6.3 Thyrotropin-Releasing Hormone -- 5.6.4 Other Peptides and Proteins -- 5.6.5 Nucleic Acid Therapeutics -- 5.7 Safety Considerations."]
[{"$nulls":4},"5.8 Conclusion."]
[null,null,null,"Sommario/riassunto","The book provides essential insights into the revolutionary potential of nanotechnology in medicine, exploring innovative approaches that harness natural materials for targeted and effective disease management. Nanotechnology has emerged as an innovative field with the potential to transform various sectors, including medicine and allied health sciences. Bioactive nanotherapeutics, a specific area within nanotherapeutics, utilizes natural materials or biomimetic designs to offer distinct advantages such as targeted drug delivery, biocompatibility, and improved therapeutic efficacy. These bioactive-based nanotherapeutics are used in the treatment and management of various diseases. Bioactive-Based Nanotherapeutics explores this rapidly growing field of therapeutics. It presents a broad overview of the fundamentals of bioactive nanomaterials, their design strategies, and their therapeutic applications. Leading experts from different disciplines have contributed chapters that explore a diverse range of topics, including the basics of bioactive nanotherapeutics, isolation methods of different bioactive compounds, and formulation developments. This volume addresses the importance of nanotechnology for the treatment and management of different diseases, including nasal, gastrointestinal, rectal, and transdermal diseases. Readers will find the book:  Provides scientific research and evidence that supports the effectiveness of bioactive-based nanocarriers in treating diseases; Explores actionable steps and real-life scenarios to illustrate the practical benefits; Provides a comprehensive guide that explains the holistic approach, explaining health-related applications of bioactive-based nanoformulations.  Audience Pharmacists, biologists, chemists, doctors, academics, and industry professionals interested in holistic and bioactive-based methods for disease treatment."]